Invicro’s Discovery and Preclinical Services Advances the Study of Medicine
A picture is worth a thousand words.
That saying encapsulates Invicro’s mission to visualize and quantify biological and pathological processes to better diagnose, treat and cure disease through advanced imaging applications and informatics.
As a global research partner to the pharmaceutical, biotech, and contract research organizations, Invicro strives to enhance the discovery and development of life-changing drugs. Discovery and Preclinical Services (DPS) is a critical part of Invicro that focuses on preclinical research for translation of drugs to the clinic. Here is more information about the DPS team and the pivotal role it plays for Invicro and drug discovery.
DPS Supports the First Steps in Drug Discovery
Preclinical research is a requirement for the discovery, characterization and early development of new drugs. The DPS team provides in-depth discovery research services including scientific expertise and study design, pharmacology, radiology imaging and tissue imaging techniques. The data generated in-house assists pharmaceutical companies at various stages in drug development including the prioritization of new molecular entities at the beginning of drug discovery to the lead optimization stages and the critical step of selecting which new molecular entity to advance to clinical testing. The data is often included in the preclinical portion of an Investigational New Drug Application (IND) and used to demonstrate a drug’s ability to reach the required tissue (while limiting exposure to non-target tissues) and engage the target (pharmacokinetics) and elicit the anticipated activity (pharmacodynamics).
DPS’s capabilities work across all major and many orphan cancers, the full spectrum of neuro/brain disorders including Alzheimer’s and Parkinson’s, and many other diseases including rare genetic disorders where gene therapy is being tested using a variety of imaging approaches. DPS uses a comprehensive array of high-tech imaging modalities including the same ones used in human patients (MRI, PET, SPECT, CT, ultrasound) and others more specifically designed for preclinical imaging in animal models (fluorescence, CFT, autoradiography, photoacoustic, bioluminescence).
DPS Makes an Impact on Drug Discovery
In FY21, the DPS team had 238 open studies, completed 162 studies, and worked with 117 clients. Invicro services its clients through multiple global sites with preclinical imaging facilities in Boston, Michigan, San Diego, New Haven, London, UK, and Hull, UK. There was also an exciting move this year with DPS relocating their Boston discovery lab to Needham, Massachusetts, offering an additional 7,000 square feet of lab space and a new state-of-the art MRI system. The move enables the team to scale their pharmacology, pathology, radiochemistry and imaging services.
DPS Employees Have a Variety of Scientific and Technology Backgrounds
The execution of DPS’s work requires the skills of many scientific disciplines and the organizational structure to enable the complex coordination of all facets of the experiment, including animal model generation, radiochemistry development and complex multi-modal imaging studies.
DPS’s diverse teams of experts have backgrounds in neuroscience, oncology, inflammation, cardiovascular disease and musculoskeletal disease to name but a few, as well as technical backgrounds in imaging modalities and instrumentation collectively resulting in a long history designing and executing imaging and pathology studies. The team of over 60 members is comprised of imaging scientists, project managers, and laboratory scientists who work closely with our Image Analysis, Advanced Pathology Services (APS), and Scientific and Medical Services (SMS) teams to support our Sponsors with the design, execution, analysis, reporting, and interpretation of preclinical research studies. Our recent customer survey (November 2021) delivered a 95% customer satisfaction score with 100% of respondents wanting to work with Invicro again, highlighting the strong scientific collaboration and relationships that are the foundation of the DPS team.
Bringing New Drugs to Market
Invicro and DPS are helping clients create new drugs to tackle disease. The work starts with DPS to help clients understand early drug behavior and translate the knowledge to provide effective and useful data for future clinical studies. Approximately 37% of the preclinical work executed by the DPS team is directly geared towards clinical translation and there are many successful examples within the company whereby Invicro managed the translation of a drug from the DPS team through to the clinical exemplifying the end-to-end service which Invicro offers/privedes to our Sponsors.
Invicro’s Discovery and Preclinical Services Advances the Study of Medicine
A picture is worth a thousand words.
That saying encapsulates Invicro’s mission to visualize and quantify biological and pathological processes to better diagnose, treat and cure disease through advanced imaging applications and informatics.
As a global research partner to the pharmaceutical, biotech, and contract research organizations, Invicro strives to enhance the discovery and development of life-changing drugs. Discovery and Preclinical Services (DPS) is a critical part of Invicro that focuses on preclinical research for translation of drugs to the clinic. Here is more information about the DPS team and the pivotal role it plays for Invicro and drug discovery.
DPS Supports the First Steps in Drug Discovery
Preclinical research is a requirement for the discovery, characterization and early development of new drugs. The DPS team provides in-depth discovery research services including scientific expertise and study design, pharmacology, radiology imaging and tissue imaging techniques. The data generated in-house assists pharmaceutical companies at various stages in drug development including the prioritization of new molecular entities at the beginning of drug discovery to the lead optimization stages and the critical step of selecting which new molecular entity to advance to clinical testing. The data is often included in the preclinical portion of an Investigational New Drug Application (IND) and used to demonstrate a drug’s ability to reach the required tissue (while limiting exposure to non-target tissues) and engage the target (pharmacokinetics) and elicit the anticipated activity (pharmacodynamics).
DPS’s capabilities work across all major and many orphan cancers, the full spectrum of neuro/brain disorders including Alzheimer’s and Parkinson’s, and many other diseases including rare genetic disorders where gene therapy is being tested using a variety of imaging approaches. DPS uses a comprehensive array of high-tech imaging modalities including the same ones used in human patients (MRI, PET, SPECT, CT, ultrasound) and others more specifically designed for preclinical imaging in animal models (fluorescence, CFT, autoradiography, photoacoustic, bioluminescence).
DPS Makes an Impact on Drug Discovery
In FY21, the DPS team had 238 open studies, completed 162 studies, and worked with 117 clients. Invicro services its clients through multiple global sites with preclinical imaging facilities in Boston, Michigan, San Diego, New Haven, London, UK, and Hull, UK. There was also an exciting move this year with DPS relocating their Boston discovery lab to Needham, Massachusetts, offering an additional 7,000 square feet of lab space and a new state-of-the art MRI system. The move enables the team to scale their pharmacology, pathology, radiochemistry and imaging services.
DPS Employees Have a Variety of Scientific and Technology Backgrounds
The execution of DPS’s work requires the skills of many scientific disciplines and the organizational structure to enable the complex coordination of all facets of the experiment, including animal model generation, radiochemistry development and complex multi-modal imaging studies.
DPS’s diverse teams of experts have backgrounds in neuroscience, oncology, inflammation, cardiovascular disease and musculoskeletal disease to name but a few, as well as technical backgrounds in imaging modalities and instrumentation collectively resulting in a long history designing and executing imaging and pathology studies. The team of over 60 members is comprised of imaging scientists, project managers, and laboratory scientists who work closely with our Image Analysis, Advanced Pathology Services (APS), and Scientific and Medical Services (SMS) teams to support our Sponsors with the design, execution, analysis, reporting, and interpretation of preclinical research studies. Our recent customer survey (November 2021) delivered a 95% customer satisfaction score with 100% of respondents wanting to work with Invicro again, highlighting the strong scientific collaboration and relationships that are the foundation of the DPS team.
Bringing New Drugs to Market
Invicro and DPS are helping clients create new drugs to tackle disease. The work starts with DPS to help clients understand early drug behavior and translate the knowledge to provide effective and useful data for future clinical studies. Approximately 37% of the preclinical work executed by the DPS team is directly geared towards clinical translation and there are many successful examples within the company whereby Invicro managed the translation of a drug from the DPS team through to the clinical exemplifying the end-to-end service which Invicro offers/privedes to our Sponsors.